Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)

Summary

It is a multi-center, prospective, open-label, two-stage optimized design, single-arm, phase II clinical study to evaluate the efficacy and safety of GB226 for the treatment of relapsed and refractory peripheral T cell lymphoma (PTCL), and to evaluate the immunogenicity of GB226.

Timeline

Start

2018-07-02

Primary completion

2021-08

Completion

2022-12-30

Publications

• Lou N, Yang M, Xie Z, Gao R, Zhang L, Tang L, Yao J, Han X, Shi Y. JAK3 A573V and JAK3 M511I mutations in peripheral T-cell lymphoma mediating resistance to anti-PD-1 therapy through the STAT3/PD-L1 pathway. J Immunother Cancer. 2025 Apr 8;13(4):e010783. doi: 10.1136/jitc-2024-010783.
• Shi Y, Wu J, Wang Z, Zhang L, Wang Z, Zhang M, Cen H, Peng Z, Li Y, Fan L, Guo Y, Ma L, Cui J, Gao Y, Yang H, Zhang H, Wang L, Zhang W, Zhang H, Xie L, Jiang M, Zhou H, Shuang Y, Su H, Ke X, Jin C, Du X, Du X, Liu L, Xi Y, Ge Z, Feng R, Zhang Y, Zhou S, Xie F, Wang Q. Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002). J Hematol Oncol. 2021 Jan 12;14(1):12. doi: 10.1186/s13045-021-01033-1.

Drugs

Indications